SequelSEC

BIOMARIN PHARMACEUTICAL INC BMRN

Pharmaceutical Preparations · CIK 0001048477 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$3.41B
Fiscal year ended 2026-06-30
Operating income
$149.26M
Fiscal year ended 2026-06-30
Free cash flow
$738.18M
Fiscal year ended 2026-06-30

BIOMARIN PHARMACEUTICAL INC (BMRN) reported revenue of $3.41B and net income of $72.97M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BIOMARIN PHARMACEUTICAL INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

BIOMARIN PHARMACEUTICAL INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$3.41B
Cost of revenue$813.59M
Gross profit$2.59B
Operating income$149.26M
Net income$72.97M
Research & development$987.64M
Weighted-average diluted sharesUnavailable
Pretax income$149.11M
Income tax expense$76.14M
Diluted EPSUnavailable
Selling, general & administrative$1.37B
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

BIOMARIN PHARMACEUTICAL INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$874.00M
Total assets$11.72B
Current assets$3.97B
Total liabilities$5.40B
Current liabilities$1.66B
Total equity incl. NCI$6.32B
Temporary (mezzanine) equityUnavailable
Inventory$1.78B
Accounts receivable$1.06B
Goodwill$655.74M
Long-term debt$3.53B
Accounts payableUnavailable

Cash flow

BIOMARIN PHARMACEUTICAL INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$857.09M
Capital expenditures$118.91M
Investing cash flow-$4.75B
Financing cash flow$3.55B
Net change in cash-$339.81M
Stock-based compensation$215.33M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$152.97M

Derived

BIOMARIN PHARMACEUTICAL INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$738.18M
Gross margin76.1%
Operating margin4.4%
FCF margin21.7%
SBC / revenue6.3%
Current ratio2.39x
Revenue YoY growth11.2%
Net margin2.1%
R&D / revenue29.0%
CapEx / revenue3.5%
Long-term debt / equity0.56x
Effective tax rate51.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BMRN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-02View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.